Nls Pharmaceutics Stock Analysis

NLSP -  USA Stock  

USD 3.32  0.27  8.85%

The big decline in price over the last few months for Nls Pharmaceuticsmay encourage insiders to take a closer look at the firm as it is trading at a share price of 3.32 on 201,000 in trading volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Nls Pharmaceutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.57. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Nls Pharmaceutics partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

The Nls Pharmaceutics stock analysis report makes it easy to digest most publicly released information about Nls Pharmaceutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Nls Pharmaceutics stock analysis module also helps to analyze the Nls Pharmaceutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Nls Pharmaceutics Stock Analysis Notes

The company had not issued any dividends in recent years. NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about Nls Pharmaceutics contact the company at 41 41 618 80 00 or learn more at

Nls Pharmaceutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Nls Pharmaceutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Nls Pharmaceutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Nls Pharmaceutics generates negative expected return over the last 90 days
Nls Pharmaceutics has high historical volatility and very poor performance
Nls Pharmaceutics was previously known as NLS Pharmaceutics and was traded on NASDAQ Exchange under the symbol NLSPW.
The company currently holds 1.37 M in liabilities. Nls Pharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
Net Loss for the year was (3.26 M).
Nls Pharmaceutics currently holds about 145.4 K in cash with (1.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Nls Pharmaceutics has a frail financial position based on the latest SEC disclosures
Latest headline from NLS Pharmaceutics Ltd gains 1.4710 percent for May 28 -

Nls Pharmaceutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Nls Pharmaceutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Nls Pharmaceutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Nls Pharmaceutics specific information freely available to individual and institutional investors to make a timely investment decision.

Nls Pharmaceutics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Nls Pharmaceutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nls Pharmaceutics backward and forwards among themselves. Nls Pharmaceutics' institutional investor refers to the entity that pools money to purchase Nls Pharmaceutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Armistice Capital LlcWarrants500 K475 K
Tower Research Capital Llc TrcCommon Shares36.5 K148 K
Millennium Management LlcCommon Shares33.2 K134 K
Clearstead Advisors LlcCommon Shares3001000
Proequities IncCommon Shares0.00.0
Note, although Nls Pharmaceutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nls Pharmaceutics Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 27.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nls Pharmaceutics's market, we take the total number of its shares issued and multiply it by Nls Pharmaceutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Nls Pharmaceutics Profitablity

Nls Pharmaceutics' profitability indicators refer to fundamental financial ratios that showcase Nls Pharmaceutics' ability to generate income relative to its revenue or operating costs. If, let's say, Nls Pharmaceutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Nls Pharmaceutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Nls Pharmaceutics' profitability requires more research than a typical breakdown of Nls Pharmaceutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(3.00) (3.24) 
Return on Average Equity 0.38  0.43 
Return on Invested Capital 0.78  0.84 

Management Efficiency

The entity has return on total asset (ROA) of (189.48) % which means that it has lost $189.48 on every $100 spent on asset. This is way below average. Nls Pharmaceutics management efficiency ratios could be used to measure how well nls pharmaceutics manages its routine affairs as well as how well it operates its assets and liabilities. Nls Pharmaceutics Return on Average Equity is very stable at the moment as compared to the past year. Nls Pharmaceutics reported last year Return on Average Equity of 0.38. As of 17th of June 2021, Return on Invested Capital is likely to grow to 0.84, while Return on Average Assets are likely to drop (3.24) . Nls Pharmaceutics Total Liabilities is very stable at the moment as compared to the past year. Nls Pharmaceutics reported last year Total Liabilities of 10.2 Million. As of 17th of June 2021, Liabilities Non Current is likely to grow to about 3.3 M, while Current Liabilities is likely to drop about 6.4 M.
Last ReportedProjected for 2021
Book Value per Share(1.29) (1.40) 
Tangible Assets Book Value per Share 0.17  0.15 
Tangible Asset Value1.2 MM

Technical Drivers

As of the 17th of June 2021, Nls Pharmaceutics secures the risk adjusted performance of (0.047514), and Mean Deviation of 3.17. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nls Pharmaceutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Nls Pharmaceutics, which can be compared to its peers in the industry. Please verify Nls Pharmaceutics information ratio and downside variance to decide if Nls Pharmaceutics is priced some-what accurately, providing market reflects its recent price of 3.32 per share. Given that Nls Pharmaceutics has jensen alpha of (0.38), we recommend you to check Nls Pharmaceutics's last-minute market performance to make sure the company can sustain itself at a future point.

Nls Pharmaceutics Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Nls Pharmaceutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Nls Pharmaceutics Technical and Predictive Indicators

Nls Pharmaceutics Forecast Models

Nls Pharmaceutics time-series forecasting models is one of many Nls Pharmaceutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nls Pharmaceutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Nls Pharmaceutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nls Pharmaceutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nls Pharmaceutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Nls Pharmaceutics. By using and applying Nls Pharmaceutics Stock analysis, traders can create a robust methodology for identifying Nls Pharmaceutics entry and exit points for their positions.
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Current Nls Pharmaceutics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nls Pharmaceutics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nls Pharmaceutics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.0Strong Buy2Odds
Nls Pharmaceutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Nls Pharmaceutics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Nls Pharmaceutics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Nls Pharmaceutics, talking to its executives and customers, or listening to Nls Pharmaceutics conference calls.
Nls Pharmaceutics Analyst Advice Details

Nls Pharmaceutics Stock Analysis Indicators

Nls Pharmaceutics stock analysis indicators help investors evaluate how Nls Pharmaceutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nls Pharmaceutics shares will generate the highest return on investment. By understating and applying Nls Pharmaceutics stock analysis, traders can identify Nls Pharmaceutics position entry and exit signals to maximize returns.
Quick Ratio0.04
Fifty Two Week Low2.3500
Float Shares3.01M
Fifty Two Week High3.8900
Average Daily Volume Last 10 Day1.26M
Average Daily Volume In Three Month1.26M
Fifty Day Average2.7550
Two Hundred Day Average2.7550
Additionally, see Stocks Correlation. Note that the Nls Pharmaceutics information on this page should be used as a complementary analysis to other Nls Pharmaceutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Nls Pharmaceutics Stock analysis

When running Nls Pharmaceutics stock analysis, check to measure Nls Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nls Pharmaceutics is operating at the current time. Most of Nls Pharmaceutics' stock examination focuses on studying past and present price action to predict the probability of Nls Pharmaceutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nls Pharmaceutics' price. Additionally, you may evaluate how the addition of Nls Pharmaceutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
The market value of Nls Pharmaceutics is measured differently than its book value, which is the value of Nls Pharmaceutics that is recorded on the company's balance sheet. Investors also form their own opinion of Nls Pharmaceutics stock's value that differs from its market value or its book value, called intrinsic value, which is Nls Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nls Pharmaceutics' market value can be influenced by many factors that don't directly affect Nls Pharmaceutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nls Pharmaceutics' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Nls Pharmaceutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nls Pharmaceutics' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.